Cargando…

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor

The use of antiplatelet agents, specifically the thienopyridines, has become a standard of care in the approach to the patient presenting with an acute coronary syndrome. These drugs irreversibly inhibit the platelet by permanently binding to the surface P2Y12 receptor and blocking the downstream fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birkeland, Kade, Parra, David, Rosenstein, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262315/ https://www.ncbi.nlm.nih.gov/pubmed/22282698 http://dx.doi.org/10.2147/JBM.S9650

Ejemplares similares

Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
por: Marczewski, Margaret M, et al.
Publicado: (2010)

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
por: Abergel, Eitan, et al.
Publicado: (2010)

A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases
por: Tao, Luyuan, et al.
Publicado: (2022)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
por: Lombo, Bernardo, et al.
Publicado: (2011)

Critical appraisal of ticagrelor in the management of acute coronary syndrome
por: Nawarskas, James J, et al.
Publicado: (2011)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention
por: Gao, Song-Tao, et al.
Publicado: (2023)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
por: Zeymer, Uwe
Publicado: (2013)

Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial
por: Lee, Yong-Joon, et al.
Publicado: (2021)

Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018)

Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
por: Berger, Jeffrey S.
Publicado: (2018)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients Non-Sensitive to Aspirin
por: Khan, Hamzah, et al.
Publicado: (2020)

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
por: Tersalvi, Gregorio, et al.
Publicado: (2020)

Dyspnoea management in acute coronary syndrome patients treated with ticagrelor
por: Parodi, Guido, et al.
Publicado: (2015)

Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials
por: Li, Jingyuan, et al.
Publicado: (2023)

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Antiplatelet therapy for elderly patients with Acute Coronary Syndromes
por: Savonitto, Stefano, et al.
Publicado: (2018)

Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes
por: Tayeb, Hussam M, et al.
Publicado: (2010)

Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome
por: Verdoia, Monica, et al.
Publicado: (2021)

A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes
por: Alkhalil, Mohammad, et al.
Publicado: (2022)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

Dual antiplatelet therapy for reduction in mortality in patients with acute and chronic coronary syndromes
por: Lesiak, Maciej, et al.
Publicado: (2021)

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
por: Davis, Estella M, et al.
Publicado: (2013)

Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease
por: Tam, Chor-Cheung, et al.
Publicado: (2022)

Spontaneous subdural hematoma and antiplatelet therapy: Does efficacy of Ticagrelor come with added risk?
por: Suryanarayana Sharma, Pattanagere Manjunatha, et al.
Publicado: (2015)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
por: Marcano, Ana Lucrecia, et al.
Publicado: (2022)

Antiplatelet Therapy for Acute Respiratory Distress Syndrome
por: Chen, Chuan-Mu, et al.
Publicado: (2020)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome
por: Moon, Hyeyeon, et al.
Publicado: (2021)

Hospital‐Level Variation in Ticagrelor Use in Patients With Acute Coronary Syndrome
por: Ozaki, Aya F., et al.
Publicado: (2022)

Effect of altitude on ticagrelor-induced dyspnea in patients with acute coronary syndrome
por: Kocabay, Gonenc, et al.
Publicado: (2023)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy
por: Janzon, M, et al.
Publicado: (2015)

Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes
por: De Rosa, Roberta, et al.
Publicado: (2019)

Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: awaiting for evidence
por: Liga, Riccardo, et al.
Publicado: (2021)

Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues
por: Verdoia, Monica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lorakeprd5354fvp9b8rfvltd7